<DOC>
	<DOC>NCT01562587</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to determine the pharmacokinetics of activated recombinant human factor VII (NovoSeven®) in haemophiliac patients in a non-bleeding state.</brief_summary>
	<brief_title>Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age 1855 years and congenital haemophilia A or B male with severe FVIII or FX deficiency +/inhibitors Age between 312 years and congenital haemophilia A or B male with record of inhibitors Known hypersensitivity to activated recombinant human factor VII or any of its components Known clinical relevant coagulation diseases or insufficiencies other than congenital haemophilia Clinical manifestation of HIV (human immunodeficiency virus) and/or protease inhibitor treatment Clinical manifestation of active/recent bleeding Administration of coagulation factor preparations within 24 hours of NovoSeven trial product dose administration Body Mass Index (BMI) outside normal range Known abuse of elicit drugs and/or alcohol Renal insufficiency Hepatic disease Cardiovascular disease Any disease or condition which, judged by the Investigator, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>